Retatrutide and Muscle Loss: What the First DXA Scan Data Shows

One of the key selling points of retatrutide over earlier GLP-1 drugs was the claim that its glucagon receptor activity would protect muscle tissue during weight loss. The first DXA scan data is in. That claim doesn't hold up.

The Glucagon Receptor Hypothesis

Retatrutide is a triple agonist — it activates GLP-1, GIP, and glucagon receptors simultaneously. This is what gives it its exceptional fat loss profile compared to semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP).

The glucagon receptor component was theorized to provide a muscle-protective advantage. Glucagon plays roles in fuel mobilization and protein metabolism, and there was mechanistic rationale for thinking that glucagon receptor activation might preferentially drive fat oxidation while sparing lean tissue.

What the DXA Data Shows

The first DXA scan data on retatrutide contradicts the muscle-protection hypothesis. The lean mass loss ratio on retatrutide is comparable to other GLP-1 agonists that don't have glucagon receptor activity.

There is no meaningful muscle-sparing advantage from the glucagon receptor agonism at the doses studied. Users still lose lean mass alongside fat — in the same proportions seen with semaglutide or tirzepatide.

The numbers differ significantly based on dose. Much of the data circulating online involves doses up to 12mg, which is far higher than what most clinical users employ. At clinical doses (typically 1–4mg per week), the fat loss is substantial and lean mass loss is proportional but less dramatic in absolute terms. However, the ratio remains the same — the glucagon receptor isn't providing the protective effect that was hypothesized.

There Is No Shortcut Around the Foundations

This data reinforces a principle that applies across the GLP-1 drug class: the fundamentals of muscle preservation still apply.

If you want to maintain or build muscle on a GLP-1 drug — including retatrutide — you need to:

Eat sufficient protein. The standard recommendation is 1.6–2.2g per kg of bodyweight daily. On a GLP-1 drug where appetite is suppressed, many people naturally undereat protein, which accelerates lean mass loss. This requires deliberate tracking.

Train with resistance. Progressive resistance training provides the mechanical stimulus that tells the body to preserve and build muscle. Without it, caloric deficits — regardless of the drug — will include lean mass loss.

No peptide, drug, or supplement overrides these two fundamentals. Retatrutide's glucagon component is a meaningful driver of fat loss. It is not a muscle-preservation shortcut.

What This Means for Retatrutide Users

The headline is clarifying, not discouraging. Retatrutide remains one of the most powerful fat loss tools in the current pharmacological toolkit — producing fat loss that significantly outperforms earlier GLP-1 drugs in head-to-head data.

But the approach should be:

  1. Protein first at every meal — prioritize hitting targets before calories
  2. Resistance training 3–4× per week — compound movements, progressive overload
  3. Consider creatine monohydrate — well-evidenced for lean mass retention during caloric deficits
  4. Monitor body composition — DEXA scans or at minimum waist-to-hip ratio and muscle circumference, not just scale weight

The drug handles the fat. You handle the muscle.

The Semaglutide SEMALEAN Comparison

It's worth noting that one 2026 study (SEMALEAN) found semaglutide-treated patients showed preserved lean mass and improved muscle function compared to baseline, along with significant fat loss. The difference from other GLP-1 data may reflect study design, population, exercise protocols, and protein intake during the trial.

The muscle question in GLP-1 research remains partially open. What's clear is that the glucagon receptor in retatrutide does not appear to be the muscle-sparing advantage it was hoped to be. Body composition outcomes are determined by the lifestyle surrounding the drug, not the drug alone.

Educational content based on available DXA data and published research. Not medical advice.